NCT00300287

A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: —

Summary

This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible. The purpose of this study is to gather data on the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar and whose blood glucose levels are close to normal.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Vildagliptin

Timeline

• Start date: 2006-02-20
• Primary completion: 2007-06-26
• Completion: 2007-06-26
• First posted: 2006-03-08
• Last updated: 2017-08-02

Locations

1 site across 1 country: Germany